Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CD22 | P20273 | 2/20 | 0.36 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.36 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987055 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL29397247 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL13191000 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL30887281 | 0.87 | NANP (0.69) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL27240262 | 0.87 | NANP (0.69) | NANPL3MBTL1CD22SIGLEC7SELL | |
| Sialic Acid SCHEMBL29668416 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| Sialic Acid SCHEMBL19718196 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| Sialic Acid SCHEMBL3156058 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| SCHEMBL420656 | 0.86 | NANP (0.67) | NANPL3MBTL1SELLSELP | |
| SCHEMBL29390472 | 0.86 | NANP (0.67) | NANPL3MBTL1SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450026-A | Sialic acid for use in the treatment of psoriasis | 生命科学股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| CN-116323930-A | Cell production of sialylated di-and/or oligosaccharides | 因比奥斯公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115461057-A | Sialic acid compositions for inhibiting and treating coronavirus infection | 生命科学股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115135769-A | KDO-free production hosts for oligosaccharide synthesis | 因比奥斯公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115087740-A | Production of glycosylation products in host cells | 因比奥斯公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114450026-A | Sialic acid for use in the treatment of psoriasis | 生命科学股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-102648286-A | Method for producing proteins in pichia pastoris that lack detectable cross-binding activity to antibodies directed against host cell antigens | MERCK SHARP & DOHME | 2012-08-22 | — | — | CN | disclosed |
| CN-101484585-A | Production of sialylated N-glycans in lower eukaryotes | GLYCOFI INC (US) | 2009-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | CACYBP, MGAM, MASP2 | NANP 1105/4885L3MBTL1 2639/4885CD22 633/4885 |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, MASP2, MGAM2 | NANP 282/4885L3MBTL1 4034/4885CD22 186/4885 |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, CA14, MASP2 | NANP 357/4885L3MBTL1 3910/4885CD22 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.